Clustered Coding Variants in the Glutamate Receptor Complexes of
                    Individuals with Schizophrenia and Bipolar Disorder by Frank, René A. W. et al.
Clustered Coding Variants in the Glutamate Receptor
Complexes of Individuals with Schizophrenia and Bipolar
Disorder
Rene ´ A. W. Frank
1., Allan F. McRae
2., Andrew J. Pocklington
3, Louie N. van de Lagemaat
1, Pau Navarro
4,
Mike D. R. Croning
1, Noboru H. Komiyama
1, Sophie J. Bradley
7, R. A. John Challiss
7, J. Douglas
Armstrong
3, Robert D. Finn
1, Mary P. Malloy
5, Alan W. MacLean
5, Sarah E. Harris
6, John M. Starr
6,
Sanjeev S. Bhaskar
1, Eleanor K. Howard
1, Sarah E. Hunt
1, Alison J. Coffey
1, Venkatesh Ranganath
1,
Pano Deloukas
1 , Jane Rogers
1, Walter J. Muir
5, Ian J. Deary
6, Douglas H. Blackwood
5 , Peter M.
Visscher
2, Seth G. N. Grant
1*
1Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridgeshire, United Kingdom, 2Queensland Institute of Medical Research, Royal Brisbane Hospital,
Brisbane, Australia, 3School of Informatics, Edinburgh University, Edinburgh, United Kingdom, 4MRC Human Genetics, Institute of Genetics and Molecular Medicine,
Western General Hospital, Edinburgh, United Kingdom, 5Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, United Kingdom,
6Department of Psychology, Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, United Kingdom, 7Department of Cell
Physiology and Pharmacology, University of Leicester, Leicester, United Kingdom
Abstract
Current models of schizophrenia and bipolar disorder implicate multiple genes, however their biological relationships
remain elusive. To test the genetic role of glutamate receptors and their interacting scaffold proteins, the exons of ten
glutamatergic ‘hub’ genes in 1304 individuals were re-sequenced in case and control samples. No significant difference in
the overall number of non-synonymous single nucleotide polymorphisms (nsSNPs) was observed between cases and
controls. However, cluster analysis of nsSNPs identified two exons encoding the cysteine-rich domain and first
transmembrane helix of GRM1 as a risk locus with five mutations highly enriched within these domains. A new splice variant
lacking the transmembrane GPCR domain of GRM1 was discovered in the human brain and the GRM1 mutation cluster
could perturb the regulation of this variant. The predicted effect on individuals harbouring multiple mutations distributed in
their ten hub genes was also examined. Diseased individuals possessed an increased load of deleteriousness from multiple
concurrent rare and common coding variants. Together, these data suggest a disease model in which the interplay of
compound genetic coding variants, distributed among glutamate receptors and their interacting proteins, contribute to the
pathogenesis of schizophrenia and bipolar disorders.
Citation: Frank RAW, McRae AF, Pocklington AJ, van de Lagemaat LN, Navarro P, et al. (2011) Clustered Coding Variants in the Glutamate Receptor Complexes of
Individuals with Schizophrenia and Bipolar Disorder. PLoS ONE 6(4): e19011. doi:10.1371/journal.pone.0019011
Editor: Thomas Burne, University of Queensland, Australia
Received October 15, 2010; Accepted March 21, 2011; Published April 29, 2011
Copyright:  2011 Frank et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research funded by Genes to Cognition Program and Wellcome Trust Functional Genomics Initiative. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sg3@sanger.ac.uk
. These authors contributed equally to this work.
Introduction
Schizophrenia and bipolar disorder are common heritable
disorders showing considerable clinical and genetic overlap [1] for
which a neurobiological explanation remains wanting. Pharma-
cological studies suggest at least two molecular models: the
‘glutamate hypothesis’, arising from observations that the NMDA
(N-methyl-D-aspartate) receptor antagonists produce schizophre-
nia-like psychotic symptoms [2,3] and the ‘dopamine hypothesis’,
based on the discovery that dopaminergic antagonists are anti-
psychotics [4]. However, it is becoming apparent that glutamate
and dopamine receptors are functionally associated within
complexes, particularly via scaffold proteins [5,6], connecting
these hypotheses and highlighting the potential importance of
post-synaptic signalling proteins in these disorders.
Recent genome-wide association studies (GWAS) of schizo-
phrenia identified rare de novo copy number variation (CNV) [7]
and an increased load of micro-deletions and micro-duplications
around coding regions [8,9]. Although the causative variants are
not yet known, an hypothesis is emerging from these studies that it
is unlikely the disease is represented by a limited number of
common variants. Instead, the loci identified contain rare variants
predicted to affect a disparate selection of genes, and suggesting
multiple ‘routes’ for the aetiology of the disease [10]. Thus far,
genome-wide screens have not addressed the question of whether
rare coding single nucleotide polymorphisms (nsSNPs) might
contribute to psychiatric diseases, since they are undetectable by
CNV scans and are not represented on SNP arrays [11].
The function of both ion-channel forming (ionotropic) [12,13]
and G-protein coupled (metabotropic) [14,15] glutamate receptors
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s is in large part dependent on their physical interactions with
intracellular scaffold proteins, including the membrane-associated
guanylate kinase (MAGUK) family. Proteomic studies show that
these receptors and scaffold proteins assemble into complexes with
a diverse range of enzymes, cytoskeletal and other proteins
[16,17]. The MAGUK-associated signalling complexes (MASCs)
comprise 100–200 different proteins that in addition to binding
glutamate receptors interact with a much larger sub-cellular
architecture, the post-synaptic density (PSD) [17,18,19]. Central in
this complex are 10 hub genes that are defined on the basis of
predicted protein-protein interaction data and appear to coordi-
nate the complex mechanisms of these receptors (Supporting
Information S1) [20]. These 10 genes are subunits of the
ionotropic NMDA receptor (GRIN1, GRIN2A, GRIN2B), AMPA
(a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor
(GRIA1, GRIA2), metabotropic (GRM1) glutamate receptor, and
their MAGUK primary binding partners DLG1, DLG2, DLG3, and
DLG4, which encode SAP97, PSD93, SAP102 and PSD95,
respectively.
To address the possibility that glutamate receptors together
with their associated signalling proteins, acting alone or in
combination, contribute to genetic susceptibility in schizophrenia
and bipolar disorder, a study of rare and common coding
polymorphisms was performed. Variants that alter the amino
acid sequence, the protein structure and may be functionally
important were identified by deep sequencing exons in the
10 hub genes of 1344 individuals (Figure 1B). These individuals
were divided into those with schizophrenia, bipolar disorder and
healthy controls.
In a parallel study, we genotyped tag-SNPs within a wider set of
169 MASC genes and 96 other candidate genes. Consistent with
other genome wide association studies of schizophrenia and
bipolar disorder [10,21], this latter approach was unable to find
any significant common variants with effect on either schizophre-
nia or bipolar disorder. However, these data provided evidence
that the ten genes selected for sequencing showed significantly
more association with disease than would be expected by chance
(rank sum P=0.0034, see Supporting Information S1). Overall,
this tag-SNP data revealed only marginal association and was
unable to identify directly the specific mutations that contribute to
disease.
Results
DNA sequencing of the 10 hub genes from 503 schizophrenic,
263 bipolar and 538 ancestrally matched controls identified 62
different coding variants (non-synonymous single nucleotide
polymorphisms; nsSNPs). Of these 62 mutations, 24 were found
solely in either the schizophrenia or bipolar disorder cohort and 16
were found solely in the control group (Fisher’s exact test,
P=0.39). Since the frequency of these disease only nsSNPs or any
single coding polymorphism did not predict disease risk (Figure 1B
and Supporting Information S1), we asked whether protein
features encoded by these nsSNPs might reveal deficits associated
with the disease.
Figure 1. The frequency and clustering of nsSNPs. A) 3-dimensional Venn diagram showing the relative frequency (height) of 62 different non-
synonymous single nucleotide polymorphisms (nsSNPs; represented as blocks) from exon re-sequencing of schizophrenic, bipolar and controls. All
data points are in view and range from less than 0.1% to 45% minor allele frequency. NsSNPs found only in one of the cohorts exhibit very low
frequency compared to the common variants found in all (see supplementary datasheet S2, columns I, K and M). B) Table showing the exon re-
sequenced genes ranked by the significance of nsSNP density of their disease only nsSNP clusters. Disease only nsSNPs are variants that are found at
least once in one of the disease cohorts and were excluded from the control cohort. DLG2 is represented by two splice variants, in which nsSNPs were
found. nsSNP density is defined as the number of nsSNP per 100 codons (or residues). nsSNP clusters were identified computationally and P-values
were calculated by randomization (see Supporting Information S1).
doi:10.1371/journal.pone.0019011.g001
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within specific domains [22], we examined if mutations clustered
within a particular region of the gene. Although overall the hub
genes contained no more nsSNPs than expected (0.6 nsSNPs per
100 codons) [23], multiple disease only nsSNPs clustered within a
narrow stretch of sequence within particular genes. Ranking the
genes using a measure of their cluster density and correcting for
multiple testing (Supporting Information S1) showed that the most
significant among these was a cluster found in GRM1, the
metabotropic glutamate receptor subtype 1 (mGluR1) (Figure 1C).
mGluR1 exists as a dimer at the post-synaptic membrane and
upon ligand binding triggers a ‘Venus flytrap-like’ conformational
change that is transduced by the cysteine-rich domain (CRD) to
bring two membrane spanning G-protein couple receptor (GPCR)
domains into apposition and activate a second messenger cascade
[24] (Figure 2B). The GRM1 cluster of 5 nsSNPs is highly unusual
(permutation test, P=0.004, see Supporting Information S1)
spanning only 56 amino acid residues of the small CRD and
neighbouring first transmembrane helix of the GPCR domain
(Figure 2A). Moreover, sequence conservation analysis (Sift and
PolyPhen, see Supporting Information S1) predicted that most of
the deleterious nsSNPs in GRM1 fell within this cluster (Figure 2A).
All but one (K563N) of the nsSNPs found in the control cohort are
excluded from the disease cluster (Figure 2A).
In order to gain further insight into the potential effect of these
polymorphisms on the GRM1 receptor, the nsSNP cluster was
mapped onto available protein models (Figure 2A) and the gene
structure (Figure 3A). Three of the nsSNPs were located in the
CRD [25] for which a highly similar (46% identity) structural
homolog is available (Figure 2B, C). The CRD is a small domain
whose rigid structure is defined by seven disulphide bond-forming
cysteines and is encoded by exons 5 and 6. These CRD nsSNPs lie
in exon 6 and are within one to three residues of at least one
cysteine. On nsSNP, L575V, is of particular interest since it
encodes on an important b-turn with positive w-torsion angle and
is highly likely to form the nucleation site for protein folding
[26,27], which precedes the formation of disulphide bonds
[28,29]. The structural propensity for a valine in this position is
negligible [30] (see Supporting Information S1). It is therefore
possible these mutations affect protein folding [31], trafficking or
activation of the receptor [32]. Preliminary data suggest that none
of the mutations affect GRM1 signalling to phospholipase C, at
least when transiently expressed in HEK293 cells (see Supporting
Information S1). However, an effect of these mutations on
alternate mGluR1 signalling pathways has not been excluded
[33]. The CRD is present in all subtypes of the mGluR family and
has been implicated in other inherited disease [32], which further
supports the importance of this domain for the normal function of
the receptor.
The two remaining nsSNPs of the cluster lie near the edge of
exon 7, which encodes the transmembrane GPCR domain
(Figure 2A), for which there is no suitable atomic protein model
Figure 2. Mapping the GRM1 nsSNP cluster onto a model of the protein structure. A) nsSNP density plot for GRM1 illustrating the
distribution along the length of the protein. Each nsSNP is marked by an asterisk if it is found only in a disease cohort (left column), found at least
once in the disease and control cohorts (second from left column), found only in the control cohort (third from left column), predicted deleterious by
sequence conservation analysis (right column; see Supporting Information S1 and datasheet S3). P-values correspond to the significance of the
cluster’s (nsSNPs indicated in green) density. B) Protein structural model of GRM1 ligand-binding domain (LBD; blue) and cysteine-rich domains (CRD;
magenta). The model was generated by Fugue and SCWRL3 using a crystal structure of GRM3 (PDB: 2e4u) as a template (see Supporting Information
S1). The pair of LBDs mediate the formation of a GRM1 dimer. Arrows indicate the direction of movement upon ligand binding that triggers activation
of the receptor [25,58]. The dashed box indicates an enlarged inset of the CRD shown in panel C. C). Model of the GRM1 cysteine-rich domain (CRD).
Wild-type and mutant side-chains at the nsSNP loci are shown in magenta and green stick format, respectively. Three disulphide bonds all conserved
between GRM1 and GRM3 are shown in stick format and indicated by arrows.
doi:10.1371/journal.pone.0019011.g002
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splicing boundary of exons 6 and 7 (Figure 3A) and bioinformatics
analysis of splicing (see Supporting Information S1) predicts these
mutations perturb sequence elements important for alternative
splicing. Thus far no report of alternative splicing has been
reported at this junction in GRM1. Therefore we examined if there
was evidence of alternative splicing at this junction in human brain
total RNA using cerebral cortex sudden-death autopsy samples.
RT-PCR across the exon-exon boundary revealed the full length
GRM1 mRNA and the presence of an exon skipped RNA that
encoded an mGluR1 completely lacking the GPCR domain and a
short c-terminal domain (see Figure 3B and Supporting Informa-
tion S1). The junction of this novel splice variant was sequenced,
the cDNA was cloned, and the expected 68 kDa exon-skipped
receptor (skipGRM1) protein was expressed in human cells (see
Figure 3C and Supporting Information S1).
The proximity of the GRM1 nsSNP cluster to the exon 6 donor
site and exon 7 acceptor site suggest these nsSNPs might perturb
the regulatory balance of alternative splicing of this receptor.
Consistent with the discovery of GRM1 nsSNP cluster is the
discovery of exon skipping in a close homologue of GRM1, GRM3
and its association with schizophrenia [34].
The total proportion of patients carrying one of these nsSNPs
within this region of GRM1 was 0.8%, whereas the proportion of
controls was 0.2% (t-test, P=0.015). This allele frequency in cases
was similar to that of recurrent large deletions on chromosomes
22, 15 and 1, which were associated with schizophrenia at
frequencies of 0.4%, 0.3%, and 0.3%, respectively [8]. Moreover,
the repeated occurrence of apparently deleterious point mutations
within this highly conserved region of GRM1 suggest these
mutations are ‘functionally recurrent’ and may be amenable to
therapeutic intervention [35].
Several patients containing a mutation from the GRM1 cluster
also contained other nsSNPs distributed in the other hub genes,
which prompted the question if individual variants alone were
sufficient, or could act in concert with other molecular
Figure 3. Mapping the GRM1 nsSNP cluster onto the genomic structure of GRM1. A) Schematic showing the distribution of GRM1 cluster
nsSNPs within the gene structure of human GRM1. Canonical splicing of GRM1 encoding the full-length protein is shown by grey lines connecting
exons. A new alternative splice variant of GRM1 is shown by red lines, in which the transmembrane GPCR domain of GRM1 is skipped. Loci of GRM1
SNP cluster are indicated in with vertical green bars. The predicted domain structure of skipGRM1 is shown. Exons are shown as rectangles. G RM1 is
410 kb long, but for clarity introns are not shown to scale. B) Detection of an exon-skipped GRM1 (skipGRM1a and b). Total RNA from human
forebrain (sudden-death autopsy sample) was extracted. The first strand was generated by RT-PCR using poly-T oligonucleotides. Full length and
skipGRM1 were detected using oligonucleotides specific to exon 6 (F; forward-primer) and exon 9 (R; reverse primer). 100 bp DNA ladder is indicated
by horizontal black bars. Faint bands in the left lane corresponding to the novel splice junctions of skipGRM1a and b were gel-cleaned and further
PCR amplified (right lane). The sequence of the PCR products encoding the splice junction between exon 6 and 8/9 were confirmed by DNA
sequencing. The arrangements of protein domains for GRM1a and the skipGRM1a is shown. SkipGRM1a cDNA was cloned into a mammalian
expression vector with a hexa-histidine tag (see Supporting Information S1). C) Growth media and lysate of His-tagged skipGRM1a transfected
mammalian cells and non-transfected control samples were western blotted with anti-His tag antibody. SkipGRM1a expresses as a protein with an
apparent molecular of approximately 68 kDa (see methods and the complete uncropped western blot image in Supporting Information S1).
doi:10.1371/journal.pone.0019011.g003
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by genetic studies in mice with compound mutations in MAGUK
proteins [36] and NMDA receptor subunits [12] wherein the effect
of carrying multiple compound mutations is greater than that of
their parts, and results in more severe phenotypes. Similarly, since
the ‘output’ of glutamate receptor activity is predicated on the
coordinated action of the synaptic protein complex [20,37], we
asked if individual patients carrying multiple functionally impor-
tant nsSNPs distributed within different components of the
complex might contain a higher ‘genetic load’ contributing to
disease.
The predicted deleterious effect of each nsSNP was measured
taking into account multiple independent parameters including
sequence conservation, effect on structural stability, proximity to
phosphorylation sites, glycosylation sites and disulphide bonds (see
Supporting Information S1). The mean deleteriousness score was
not significantly different between nsSNPs found in the disease
cohort and control. Individuals were then scored according to the
sum of the predicted deleterious load contributed by their nsSNPs.
Combinations of two or more nsSNPs, referred to as concurrent
nsSNPs (Figure 4A) were found in 380 individuals (192
schizophrenia/bipolar and 188 controls). When individuals with
one nsSNP were compared to individuals with two and three
concurrent combinations of nsSNPs, an increased load of
deleteriousness in schizophrenic and bipolar disorder over controls
was revealed (Figure 4B). The significance of this genetic load was
estimated for subsets of individuals with increasing numbers of
concurrent nsSNPs (Figure 4C). For individuals with at least one
nsSNP there was a small 6% net increase in deleteriousness over
control, (permutation, P=0.05, see Figure 4C, outermost subset of
concentric Venn diagram). In contrast, individuals with at least two
concurrent nsSNPs the net increase in deleteriousness increased to
15%, (permutation, P=0.01, Figure 4C, second subset). For three or
more concurrent nsSNPs the net increase in deleteriousness was
also 15%, but with a diminishing number of individuals in this
subset significance is less (P=0.06, Figure 4C innermost subset).
Overall, these data are consistent with the concurrence of multiple
nsSNPs having greater adverse effects in schizophrenia and
bipolar disorder than in controls. Importantly, the genetic load
detected here is distributed among components of a receptor-
signaling complex that is fundamental to cognition and provides a
plausible genetic revision of the long-standing glutamate hypoth-
esis of psychosis disorders [2,3].
Discussion
GRM1 identified in this association study has not previously
been linked genetically with schizophrenia and bipolar disorder,
although other evidence supports its involvement in these and
other neurological disorders [38,39,40,41]. GRM1 has a well-
established role in the commonest form of mental retardation,
Fragile X syndrome [42]. The stabilisation of DLG4 mRNA is
mediated by the fragile X mental retardation protein (FMRP) and
is enhanced by GRM1 activation [43]. In addition, FMRP
regulates DLG3 translation, and DLG3 mutations also produce X-
linked mental retardation [44]. Likewise an FMRP-associated
gene, CYFIP1, containing a rare micro-deletion was found in a
recent study of copy number variants in schizophrenia [9]. Thus, a
pattern is emerging of functionally connected proteins [19] with
deficits in different yet related psychiatric diseases that suggest
GRM1 and other genes encoding synaptic components are
important for cognitive health generally [45,46,47]. The specific
effect on synaptic function that this cluster of mutations interfere
with remains to be identified, however, GRM1 plays an important
role in synaptic scaling [48], a process that may be abrogated in
schizophrenia [49] and perturbed by mutations in GRM1 that
affect splicing.
Schizophrenia and bipolar have been described in psychiatry as
a spectrum of many disorders with heterogeneous presentation,
from which it has been proposed that genetics may lead to a sub-
classification of these diseases into subtypes [50,51]. Our data is
consistent with a model in which disease subtypes might take the
form of different nsSNP clusters such as that seen GRM1. In
addition, the heterogeneity of particular combinations of concur-
rent rare and common nsSNPs and their increased genetic load of
deleteriousness in schizophrenic and bipolar individuals may also
contribute to the breadth of symptom profiles and drug responses.
Whilst categorizing disease subtypes is of immense importance,
it is likely genome-wide studies that rely on the homogeneity of the
disease cohort and measure the frequency distribution of tag-SNPs
alone [52,53,54] are biased towards variation that is common to
all subtypes of the disease and consequently may fail to detect the
most penetrant, causal alleles specific to each disease subtype.
Instead, the analysis of clustering and genetic load presented here
identified putative causal alleles directly and their biological effects
were assessed. Therefore we expect that expanding this multigenic
approach using in-depth sequencing of other sets of genes,
particularly other hubs within the synaptic proteome, will identify
other nsSNP clusters, and genetic load that may define a range of
neuropsychiatric diseases [19].
Methods
DNA samples and cohorts
The patient DNA samples (from blood) comprised Caucasian
individuals contacted through the inpatient and outpatient services
of hospitals in South East Scotland. A diagnosis of schizophrenia
or bipolar disorder was based on information from an interview
with the patient using the Schedule for Affective Disorders and
Schizophrenia–Life time version (SADS-L) supplemented by case
note review and frequently by information from medical staff,
relatives and care givers. Final diagnoses, based on DSM-IV
criteria (American Psychiatric Association 2000) were reached by
consensus between two trained psychiatrists. The control group
was composed of individuals that have undergone longitudinal
assessment for cognitive ability and did not suffer from psychiatric
disease [Lothian Birth Cohort 1921 (LBC 1921), Supporting
Information S1]. The Multi-Centre Research Ethics Committee
for Scotland approved the study and patients gave written
informed consent for the collection of DNA samples for use in
genetic studies. Re-sequencing and tag-SNP genotypes are shown
in Datasheet S1 and S5, respectively. Relationships between
individuals were investigated using the software GBR [55] with
one individual removed from any pair showing relatedness. The
results of the tag-SNP study are consistent with the absence of
significant population stratification between cases and controls
(test statistic inflation factor ‘lambda’ of 0.98, see Supporting
Information S1).
Exon re-sequencing
Exons and the flanking sequence of the ten candidate genes
were extracted from the Vega database [56], which contains high-
quality manually curated annotation. Primers were designed
automatically using Primer3 to amplify the exon and at least
125 base pairs either side of the exon. Any exons failing automatic
primer design had primers designed manually. Primer pairs were
pre-screened to determine the optimum conditions for amplifica-
tion. The majority of exons were amplified at 60uC. After
Human Mutations in NMDAR Complex
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agarose gel, to confirm the size of the PCR product. The
remaining PCR product was then ‘cleaned-up’ using two enzymes,
Exonuclease 1 and Shrimp Alkaline Phosphatase. Bi-directional
sequencing of amplicons was carried out using Big DyeTM
chemistry. SNPs were called using ExoTrace, an algorithm
developed for the detection of heterozygotes in sequence traces.
Statistical analysis of nsSNP density
The density of nsSNPs was calculated as the number of nsSNPs
within a genomic region divided by the length of that region
(defined by the nsSNP positions on the outer edges of the cluster).
The minimum cluster length was limited to 40 codons represent-
ing the approximate minimum size of a protein domain [57], since
this avoids small clusters of a few closely spaced variants becoming
highly ranked (see datasheet S3).
All possible groupings of nsSNPs within the 11 (10 hub proteins
and one additional splice variant of DLG2) proteins were
considered as a potential cluster. For each potential cluster, the
significance of the deviation from the average density was tested
using a Poisson model with an average 0.6 nsSNPs per 100 codons
and the cluster with the most significant density increase was
selected. It is of note that taking all the nsSNPs in our dataset, the
average density (0.6 nsSNPs per 100 codons) is similar to that
predicted for the human population (0.55 nsSNPs per 100 codons)
[23].
The experiment-wide significance level of the best cluster within
each gene was evaluated for each potential cluster by comparing
its p-value from a Poisson distribution to the p-values from a
Poisson distribution of randomly placed nsSNPs in each gene. This
‘extreme Poisson p-value distribution’ was constructed for each
protein isoform in the following way:
Figure 4. Analysis of the genetic load of multiple concurrent nsSNPs in individuals. A) Node diagram of concurrent nsSNPs from 33
schizophrenic and bipolar patients with $3 nsSNPs. Individuals are represented by rhombi that lie between the proteins (shaded grey). nsSNPs
shown as circles are distributed among 6 proteins labelled with gene IDs (GRIN2A, GRIN2B, GRM1, DLG1, DLG2, DLG3 and DLG4). Each unique nsSNP is
labelled with a two-letter code (see Supporting Information S1 and datasheet S4 for the key). No nsSNPs were found concurrent with nsSNPs in
GRIN1, GRIA1 or GRIA2 in any individuals in our cohorts. The combination of nsSNPs in any one patient is indicated by lines connecting an individual
to multiple nsSNPs (black and grey lines are rare (,1%) and common variants (.1%), respectively). B) Bar graph showing the mean deleteriousness
score per individual. This mean score was calculated for individuals (n=509) with 1 nsSNP, 2 concurrent nsSNPs (n=271) and 3 concurrent nsSNPs
(n=90) in disease and control (see Supporting Information S1). C) Concentric Venn diagram comparing subsets of schizophrenia/bipolar and control
individuals with $1 nsSNPs (outer subset), $2 nsSNPs (middle subset) and $3 nsSNPs (inner subset). The average deleteriousness score (see
supplementary datasheet S4) of each subset is labelled and shown as a heat-map. Significance of the difference between schizophrenia/bipolar and
control was tested statistically by permutation protocols (see Supporting Information S1). The numbers of individuals from control and disease
cohorts in each subset are shown as an inset table on the right. D) Hypothetical disease models of any one individual with disease. If a variant of any
one allele in one individual is sufficient to cause disease, the following ‘single variant’ model can be represented with a concentric Venn diagram. This
shows high deleteriousness within all subsets of individuals with varying numbers of concurrent nsSNPs. In contrast, if multiple concurrent variants
must accumulate in an individual in order that the threshold of penetrance is reached, a ‘genetic load’ model can be represented in a concentric Venn
diagram. This shows increasing deleteriousness over control that is proportional to the numbers of concurrent nsSNPs.
doi:10.1371/journal.pone.0019011.g004
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performed.
2) In each randomization replicate, all contiguous subsets of
nsSNPs were compared to the mean SNP density in that
protein isoform and the Poisson p-value of the densest subset
was recorded for each replicate.
3) One hundred thousand randomizations on each isoform
allowed us to construct a distribution of extreme Poisson
p-values for each protein isoform.
Finally, each protein’s most dense cluster Poisson p-value was
compared to the distribution of Poisson P-values obtained by
randomization. The computed significance of each protein’s best
cluster was corrected using the Benjamini-Hochberg false
discovery rate.
Statistical analysis of predicted genetic load of
deleteriousness
Multiple parameters (see Supporting Information S1) were used
to score the predicted effect of each nsSNP (scores for each
parameter are presented in datasheets S2 and S4). The significance
of the difference in the average deleteriousness scores for individuals
in the case and controls groups was assessed by permutation. The
case and control labels were randomly permuted 10,000 times to
obtain the distribution of the expected difference in average
deleteriousness under the null hypothesis. As it would be expected
that the disease group had an increased deleteriousness on average,
the alternative hypothesis is one-sided and its significance was
evaluated by calculating the proportion of permuted test statistics
(datasheet S9, column J) greater than or equal to the observed value
(datasheet S9, column I). These permutation tests were also
performed on restricted subsets of individuals who carried at least
one, two or more and three or more non-synonymous variants.
Restrictingthesamplefurther into groupswithfour ormore wasnot
investigated due to the restricted sample sizes that would result in
low statistical power to significantly detect any difference. P-values
are shown in supplementary datasheet S9, column L.
Detection and cloning of exon-skipped GRM1
Total RNA was extracted from sudden-death autopsy brain
samples (dorso-lateral prefrontal cortex). GRM1 splice variants
were amplified, sequenced and cloned by PCR (see Figure 4 and
Supporting Information S1).
Tag-SNP genotyping
Tag-SNPs within a wider set of 169 MASC genes and 96 other
candidates (see datasheets S6 and S7) were genotyped. tag-SNPs
were selected for 265 genes using the Tagger Pair-wise method on
HapMap PhaseII CEU data. We aimed to assay 10 kb flanks
upstream and downstream of each gene and used the parameters
minimum R
2 of 0.8 and minimum minor allele frequency of 0.05.
SNPs were submitted to Illumina for GoldenGate assay design and
those judged to be viable assay targets (design score .=0.4) were
ordered as 3 Oligo Pool Assays. 12 assays were repeated in all 3
pools as a quality control measure. Consistent with other genome
wide association studies of schizophrenia and bipolar disorder
[10,21], tag-SNP genotyping was unable to find any single
common variants significantly associated with either schizophrenia
or bipolar disorder. However, these data provided evidence that
the ten genes selected for sequencing showed significantly more
association with disease than would be expected by chance (rank
sum P=0.0034, see Supporting Information S1 and Datasheet
S8). Overall, this tag-SNP data revealed only marginal association
and is incapable of directly identifying the specific mutations that
contribute to disease. Detailed methods have been described in
Supporting Information S1.
Supporting Information
Supporting Information S1 Document contains detailed
methods for the detection and analysis of coding variants,
investigations into the GRM1 nsSNP cluster, tag-SNPs, and the
control cohort (LBC).
(DOC)
Datasheet S1 Exon re-sequencing genotypes from schizophre-
nia, bipolar disorder and control (LBC). First and second columns
indicate patient code and their cohort, respectively. The remaining
columns are headed by nsSNP names, under which are the
genotypes for each individual.
(XLS)
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